|Systematic (IUPAC) name|
|Biological half-life||2 hours|
|ATC code||C09AA06 (WHO)|
|Molar mass||438.516 g/mol|
|Melting point||120 to 130 °C (248 to 266 °F)|
Quinapril (marketed under the brand name Accupril by Pfizer) is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. A prodrug, it is converted to its active metabolite, quinaprilat, in the liver.
Mechanism of action
Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful vasoconstrictor and increases blood pressure through a variety of mechanisms. Due to reduced angiotensin production, plasma concentrations of aldosterone are also reduced, resulting in increased excretion of sodium in the urine and increased concentrations of potassium in the blood.
Quinapril is indicated for the treatment of high blood pressure (hypertension) and as adjunctive therapy in the management of heart failure. It may be used for the treatment of hypertension by itself or in combination with thiazide diuretics, and with diuretics and digoxin for heart failure.
- Impaired renal and liver function
- Patients with a history of angioedema related to previous treatment with an ACE inhibitor
- Hypersensitivity to quinapril